Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target Raised to $38.00 at Truist Financial

Centessa Pharmaceuticals (NASDAQ:CNTA) had its target price increased by Truist Financial from $33.00 to $38.00 in a report published on Thursday morning,Benzinga reports. Truist Financial currently has a buy rating on the stock.

Other analysts also recently issued reports about the company. Oppenheimer increased their price objective on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. B. Riley increased their price target on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, December 1st. Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 27th. Chardan Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. Finally, Wells Fargo & Company increased their target price on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.50.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $24.89 on Thursday. The business has a 50 day moving average of $25.63 and a 200-day moving average of $22.30. The company has a market capitalization of $3.35 billion, a P/E ratio of -13.60 and a beta of 1.56. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $30.58. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, equities research analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Activity

In other Centessa Pharmaceuticals news, CTO Tia L. Bush sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the transaction, the chief technology officer directly owned 121,503 shares in the company, valued at approximately $3,159,078. This represents a 24.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mario Alberto Accardi sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the sale, the insider directly owned 178,801 shares of the company’s stock, valued at approximately $5,364,030. This trade represents a 5.30% decrease in their position. The SEC filing for this sale provides additional information. 7.09% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CNTA. TD Waterhouse Canada Inc. acquired a new stake in Centessa Pharmaceuticals in the fourth quarter worth $25,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Centessa Pharmaceuticals by 26.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after purchasing an additional 979 shares in the last quarter. DNB Asset Management AS acquired a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at about $218,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at about $218,000. Finally, GSA Capital Partners LLP bought a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at about $455,000. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.